tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksChatGPT StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert CenterTipRanksAI
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Daily Analyst Ratings
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
ChatGPT Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

AVIR Stock Latest News

Atea Pharmaceuticals completes patient enrollment in Phase 3 SUNRISE-3 trial
The FlyAtea Pharmaceuticals completes patient enrollment in Phase 3 SUNRISE-3 trial
23d ago
AVIR
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
PremiumPress Releases
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
23d ago
AVIR
Atea Pharmaceuticals reports Q4 EPS (47c), consensus (51c)
PremiumThe Fly
Atea Pharmaceuticals reports Q4 EPS (47c), consensus (51c)
2M ago
AVIR
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
PremiumPress Releases
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2M ago
AVIR
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19
PremiumPress Releases
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19
3M ago
AVIR
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PremiumPress ReleasesAtea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
4M ago
AVIR
Atea treatment of disease caused by dengue virus granted FDA orphan status
PremiumThe Fly
Atea treatment of disease caused by dengue virus granted FDA orphan status
4M ago
AVIR
Atea Pharmaceuticals’ combination candidate for hepatitis C shows protential
PremiumThe Fly
Atea Pharmaceuticals’ combination candidate for hepatitis C shows protential
5M ago
AVIR
Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
PremiumPress Releases
Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
5M ago
AVIR
Atea Pharmaceuticals reports Q3 EPS (40c), consensus (48c)
PremiumThe Fly
Atea Pharmaceuticals reports Q3 EPS (40c), consensus (48c)
5M ago
AVIR
Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
PremiumPress Releases
Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
5M ago
AVIR
Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences
PremiumPress Releases
Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences
5M ago
AVIR
Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023
PremiumPress ReleasesAtea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023
6M ago
AVIR
Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
PremiumPress Releases
Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
8M ago
AVIR
Buy/Sell: Wall Street’s top 10 stock calls this week
PremiumThe Fly
Buy/Sell: Wall Street’s top 10 stock calls this week
8M ago
W
LLY
Atea Pharmaceuticals downgraded to Underweight from Neutral at JPMorgan
PremiumThe Fly
Atea Pharmaceuticals downgraded to Underweight from Neutral at JPMorgan
8M ago
AVIR
Atea Pharmaceuticals reports Q2 EPS (34c), consensus (47c)
PremiumThe Fly
Atea Pharmaceuticals reports Q2 EPS (34c), consensus (47c)
8M ago
AVIR
Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
PremiumPress Releases
Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
8M ago
AVIR
Atea announces first patient dosed in Phase 2 study of bemnifosbuvir, ruzasvir
PremiumThe Fly
Atea announces first patient dosed in Phase 2 study of bemnifosbuvir, ruzasvir
10M ago
AVIR
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
PremiumPress ReleasesAtea Pharmaceuticals to Present at the Jefferies Healthcare Conference
11M ago
AVIR
Atea Pharmaceuticals’ Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences
PremiumPress Releases
Atea Pharmaceuticals’ Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences
11M ago
AVIR
Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences
PremiumPress Releases
Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences
11M ago
AVIR

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >